HomeAI · summaries
Storia in 2 fonti
FDA Expands Risankizumab Label in Psoriatic Disease
IL-23 inhibitor lands indications for kids 6 years and up
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
- ·
medpagetoday.com
FDA Expands Risankizumab Label in Psoriatic Disease
IL-23 inhibitor lands indications for kids 6 years and up